Study of Gemcitabine and Carboplatin in the postoperative adjuvant therapy of Cholangiocarcinoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17010749

Enrollment

Unknown

Registered

2017-02-28

Start date

2017-02-26

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Interventions

1:Gemcitabine

2:Gemcitabine+Carboplatin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Disease characteristics: (1) To be confirmed cholangiocarcinoma by pathology or cytology examination; (2) Total resection (R0 or R1) or partial resection (R2). 2. Patient characteristics: (1) signed informed consent; (2) Aged >18 years; (3) Physical state: KPS score =70; (4) Life expectancy >3 months; (5) Peripheral WBC>4.0*10^9/L, PLT >80*10^9/L;

Exclusion criteria

Exclusion criteria: Abnormal ECG; Abnormal liver & renal function (TBil >1.5SD, AST\ALT >5SD, Cr >1.5SD, Ccr <45ml/min); Pregnant; History of other malignant disease (resectable skin tumor or local cervical lesions excluded); History of Gemcitabine and taxanes taken

Design outcomes

Primary

Measure	Time frame
overall survival;	—

Secondary

Measure	Time frame
toxic reactions of chemotherapy;Quality of Life;five-year survival rate;two-year survival rate;	—

Countries

China

Contacts

Public ContactQu Qiang

Peking Union Medical College Hospital

qiangqu@hotmail.com+86 010 69152611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026